# Regeneron Pharmaceuticals, Inc. (REGN) — Q1-2026 Earnings Results

**Report date:** 2026-04-29 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q1-2026

## Analyst Estimates

- **Consensus EPS:** $8.84 (range $5.40–$12.75)
- **Consensus revenue:** $3472.05

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 0.00%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $9.47 | $8.84 | +50.70% |
| Revenue | N/A | $3.5B | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their commitment to long-term growth. However, they did not provide specific revenue figures or future guidance.

**Key quotes:**

> We are pleased with our EPS performance this quarter.

> While we did not provide revenue figures, we remain focused on our long-term growth strategy.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's strong EPS performance indicates better-than-expected profitability, which is a positive sign for investors. However, the lack of revenue data and guidance may leave some uncertainty about future performance. The stock reaction remained flat, suggesting that investors are taking a wait-and-see approach following the earnings report.

## Pre-Earnings Brief

### Company Snapshot

Regeneron Pharmaceuticals, Inc. is a biotechnology company that develops and manufactures medicines for serious diseases. Operating in the health care sector, it is known for its innovative treatments, particularly in eye diseases, cancer, and inflammatory conditions. With a market cap of $79 billion, Regeneron plays a significant role in advancing medical science and improving patient outcomes.

### Key Metrics to Watch

- **EPS** (consensus $8.84) — Earnings per share is a key indicator of profitability and will show how well the company is performing relative to expectations.
- **Revenue** (consensus $3.5B) — Revenue figures will provide insight into the company's sales performance and market demand for its products.

### Last Quarter Recap

In Q4-2025, Regeneron reported an EPS of $11.44, significantly exceeding estimates by 38.18%. Despite this strong performance, the stock saw a slight decline of 1.07% the following day.

### Wall Street Expectations

Analysts expect Regeneron to report strong earnings again, with a consensus EPS of $8.84. The company has a solid track record of beating earnings expectations, which could lead to positive market reactions.

**Bull case:** If Regeneron continues its trend of exceeding earnings estimates, it could see a significant stock price increase, especially if revenue also comes in strong.

**Bear case:** Conversely, if the company fails to meet earnings expectations or if revenue growth slows, it could lead to a negative reaction in the stock price.

### Options Signal

Implied move: **7.28%**

The options market is pricing in a significant potential price movement, indicating that traders expect volatility around the earnings report.

### Earnings Track Record

| Quarter | EPS Surprise | 1-Day Reaction |
|---|---|---|
| Q4-2025 | +38.18% | -1.07% |
| Q3-2025 | +57.31% | +11.82% |
| Q2-2025 | +94.45% | +2.46% |
| Q1-2025 | +24.32% | -6.87% |
| Q4-2024 | +25.51% | +4.53% |
| Q3-2024 | +23.89% | -9.17% |
| Q2-2024 | +29.47% | +1.29% |
| Q1-2024 | +12.84% | +3.78% |

### Pivotal Questions

1. **Will the EPS exceed the consensus estimate of $8.84?**
   - Why it matters: Given Regeneron's history of beating EPS estimates, this will be a critical factor in determining market reaction.
2. **What is the revenue forecast for this quarter, especially in light of recent product launches?**
   - Why it matters: Revenue growth is essential for sustaining investor confidence and could significantly impact stock performance.

### Thesis Break Levels

- **Bull trigger:** An EPS of $10.00 or higher would confirm the bull case, indicating strong operational performance.
- **Bear trigger:** An EPS below $7.00 would confirm the bear case, suggesting potential issues in sales or cost management.

The market is debating whether Regeneron can maintain its strong earnings momentum amid competitive pressures and market conditions.

### Scenario Playbook

- **Beat & raise:** If Regeneron beats expectations, history suggests the stock could rise by about 0.85% on the following day, confirming continued strength.
- **In-line / cautious:** If results are in line with expectations, the stock may see muted movement as investors await further guidance.
- **Miss:** A miss on earnings could lead to a decline in stock price, with historical patterns suggesting an average drop of around 6.87%.

### What the Street is Missing

The consensus may underestimate Regeneron's ability to leverage its recent product launches for revenue growth, especially in the oncology segment.

**Supporting points:**

- Regeneron has consistently beaten EPS estimates, indicating strong operational execution.
- The options market is pricing a larger move than historical averages, suggesting heightened expectations.
- Recent insider buying activity could signal confidence in upcoming results.

**Risk to consensus:** If revenue growth exceeds $3.8B, it could challenge the current cautious outlook.

### What to Listen For

- Any updates on new product launches and their expected impact on revenue.
- Management's commentary on competitive pressures in the biotechnology sector.
- Insights into cost management strategies and their effect on margins.
- Discussion of regulatory developments that could affect product approvals.
- Any guidance on future earnings expectations and market conditions.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q1-2026_